Abstract Library

#4585 Short-term observation of liver transplantation combined with multidisciplinary integrated treatment of liver metastases from neuroendocrine tumours beyond the Milan criteria

Introduction: The continuous progress of comprehensive treatment enables neuroendocrine tumour liver metastasis (NENLM) that meets Milan criteria to achieve longer survival without liver transplantation (LT). LT often faces high tumour burden, while comprehensive treatment also brings new opportunities for recurrence.

Conference:

Presenting Author: Chen C

Authors: Chen C, Jiang W, Chen J, Liang Y, Xie Y,

Keywords: liver transplantation, neuroendocrine tumour liver metastasis, Milan Criteria, comprehensive treatment,

#4560 Genetic trajectory and clonal evolution of non-functional pancreatic neuroendocrine tumours with lymph node and liver metastasis

Introduction: The systemic spread of panNETs is dominated by lymphatic reflux and portal system, exhibiting diverse patterns of metastasis without systematical genomic investigation.

Conference:

Presenting Author: Wu J

Authors: Wu J, Peng Y, Yin L, Jiang K, Li Q,

Keywords: Pan NET, Metastasis, Whole exome sequencing, Pylogenic tree,

#4541 Prognosis analysis of metastatic rectal neuroendocrine tumour: Liver-directed trans arterial embolisation may play a pivotal role

Introduction: Rectal neuroendocrine tumour (rNET) is prone to metastasis, and distant metastasis is associated with worse prognosis. However, factors influencing the prognosis of metastatic rNET and the recommended treatments remain controversial.

Conference:

Presenting Author: Yang Y

Authors: Yang Y, Chen L, Liu M, Jiang Y, Lin Y,

Keywords: metastatic rectal neuroendocrine tumour, liver metastasis, trans arterial embolisation, inverse probability of treatment weighting, overall survival,

#4524 SIRT7 drives the radioresistance of pancreatic neuroendocrine tumours via the DNMT1-MEN1 axis

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are a rare and highly heterogeneous type of tumour in the pancreas. After failure of standard treatment, patients have poor prognoses. Radiotherapy may be a potential therapeutic modality for such patients. However, PanNETs usually exhibit a radiation “cold” tumour through unclarified mechanisms.

Conference:

Presenting Author: Jianyun J

Authors: Jiang J, Xu J, Liang Y, Chen L, Ji S,

Keywords: pancreatic neuroendocrine tumour, radio resistance, SIRT7, MEN1,

#4501 Efficacy and safety of surufatinib in unresectable or metastatic grade 3 neuroendocrine tumours (NET G3): A national multi-centre, retrospective study

Introduction: Currently, there are limited treatment options for NET G3 and therapeutics for NET G1/2 may be considered as alternatives.

Conference:

Presenting Author: Hao J

Authors: Wang J, Zhang N, Liang Y, Long J, Chi Y,

Keywords: surufatinib, NET G3,